FDA Approves POTELIGEO — Kyowa Kirin, Inc.

# FDA Approves Kyowa Kirin's POTELIGEO for Cutaneous T-Cell Lymphoma Treatment The FDA has approved Kyowa Kirin, Inc.'s POTELIGEO (mogamulizumab-kpkc), an intravenous monoclonal antibody therapy, positioning the company to capture market share in the rare oncology segment of cutaneous T-cell lymphoma treatment. The approval expands Kyowa Kirin's oncology portfolio and establishes a differentiated therapeutic option in a limited-competition market space.